Zacks Small Cap Predicts Reduced Earnings for Soligenix

Soligenix, Inc. (NASDAQ:SNGX) – Equities researchers at Zacks Small Cap lowered their FY2025 earnings per share (EPS) estimates for shares of Soligenix in a research note issued on Tuesday, May 13th. Zacks Small Cap analyst D. Bautz now anticipates that the biopharmaceutical company will post earnings per share of ($3.45) for the year, down from their previous forecast of ($3.09). The consensus estimate for Soligenix’s current full-year earnings is ($4.65) per share.

Soligenix Stock Down 2.1%

Shares of NASDAQ:SNGX opened at $1.86 on Friday. The company has a market cap of $6.07 million, a P/E ratio of -0.25 and a beta of 2.06. Soligenix has a 52 week low of $1.68 and a 52 week high of $14.83. The business has a fifty day simple moving average of $2.08 and a 200-day simple moving average of $2.60.

Soligenix (NASDAQ:SNGX) last issued its quarterly earnings data on Friday, May 9th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.39). Soligenix had a negative return on equity of 223.29% and a negative net margin of 1,473.38%.

Institutional Investors Weigh In On Soligenix

An institutional investor recently raised its position in Soligenix stock. Geode Capital Management LLC raised its position in shares of Soligenix, Inc. (NASDAQ:SNGX) by 42.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 26,094 shares of the biopharmaceutical company’s stock after acquiring an additional 7,729 shares during the period. Geode Capital Management LLC owned approximately 1.04% of Soligenix worth $71,000 at the end of the most recent reporting period. 3.60% of the stock is owned by hedge funds and other institutional investors.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.